Reply to: Optimal dosing and duration of linezolid in multidrug-resistant tuberculosis: methodological and clinical appraisal
- PMID: 41571332
- DOI: 10.1183/13993003.02064-2025
Reply to: Optimal dosing and duration of linezolid in multidrug-resistant tuberculosis: methodological and clinical appraisal
Conflict of interest statement
Conflicts of interest: J-J. Yim reports support for the present study from the Patient-Centered Clinical Research Coordinating Center (PACEN), funded by the Ministry of Health and Welfare, South Korea, and grants from Insmed Incorporated, AN2 Therapeutics and LigaChem Biosciences Inc. All other authors declare that they have no potential conflicts of interest.
Comment on
-
Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis.Eur Respir J. 2025 Aug 22;66(2):2500315. doi: 10.1183/13993003.00315-2025. Print 2025 Aug. Eur Respir J. 2025. PMID: 40675768 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources